Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Palvella Therapeutics (NASDAQ: PVLA) is set to release its Q2 2025 earnings results on August 13th, with analysts projecting a loss of ($0.81) per share for the quarter.
• The company's share price recently opened at $37.52, with a market cap of $414.97 million and a P/E ratio of -3.10.
• Palvella Therapeutics has received multiple "buy" ratings from analysts, with a consensus price target of $52.22 and several target prices reaching as high as $90.00.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($3.40) by $2.66. On average, analysts expect Palvella Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock traded up $1.85 during midday trading on Friday, reaching $40.90. 106,508 shares of the company's stock traded hands, compared to its average volume of 187,830. The company has a market cap of $452.35 million, a PE ratio of -3.38 and a beta of -0.01. The stock has a 50 day moving average of $28.49 and a 200-day moving average of $24.23. Palvella Therapeutics has a 12 month low of $11.17 and a 12 month high of $41.00.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Lifesci Capital assumed coverage on Palvella Therapeutics in a research note on Monday, August 4th. They issued an "outperform" rating and a $90.00 price target on the stock. Canaccord Genuity Group cut their target price on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. Raymond James Financial started coverage on Palvella Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $54.00 price objective on the stock. Finally, Truist Financial initiated coverage on Palvella Therapeutics in a report on Monday, July 21st. They issued a "buy" rating and a $56.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics presently has an average rating of "Buy" and an average price target of $52.40.

Hedge Funds Weigh In On Palvella Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new position in Palvella Therapeutics during the 1st quarter valued at approximately $533,000. Geode Capital Management LLC boosted its holdings in shares of Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company's stock worth $3,923,000 after purchasing an additional 79,787 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Palvella Therapeutics in the 1st quarter worth approximately $7,553,000. Hedge funds and other institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.